Federal Research Institute of Pediatric Hematology, Oncology and Immunology
57
13
17
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 57 trials
100.0%
+13.5% vs industry average
21%
12 trials in Phase 3/4
10%
1 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (57)
Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma
Role: lead
Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies
Role: lead
Study of Treosulfan-Based Conditioning for HSCT in Nijmegen Breakage Syndrome
Role: lead
Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation
Role: lead
The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia
Role: lead
Successful Treatment of Netherton Syndrome With Combination of Secukinumab and Dupilumab
Role: lead
Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis
Role: lead
Emapalumab Efficacy in Children With Primary Hemophagocytic Lymphohistiocytosis
Role: lead
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis
Role: lead
Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021)
Role: lead
Abdominal Neuroblastoma Laparoscopic Surgery Risk Factors Stratification
Role: lead
Low Dose Treosulfan Based Conditioning Regimen and PTCy in HSCT for Nijmegen Breakage Syndrome
Role: lead
PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity
Role: lead
Evaluation of Brain Changes in ALL Patients on Therapy
Role: lead
Induction Chemoimmunotherapy for Patients With High-risk Neuroblastoma
Role: lead
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis
Role: lead
Evaluation of Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety and Efficacy in the Treatment of Patients With Primary Immunodeficiencies
Role: lead
A Prospective Multicenter Clinical Trial of MRD-based Treatment Strategy in Children and Young Adults With AML
Role: lead
CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT
Role: lead
A Combination of Vemurafenib, Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E Mutation
Role: lead